Evidence-Based Peptide Intelligence
Peptide intelligence without
the bullsh*t.
94 peptides. Honest evidence ratings. Regulatory status. No vendor relationships. No hype.
Strongest Evidence
FDA-approved or strong clinical evidence
Semaglutide
therapeuticSemaglutide is an FDA-approved GLP-1 receptor agonist with the strongest clinical evidence of any peptide on the market. STEP trials: 15–17% body weight reduction. SELECT trial: 20% cardiovascular risk reduction in non-diabetic overweight patients. The defining weight-loss drug of the 2020s.
Tirzepatide
therapeuticTirzepatide is a dual GLP-1/GIP receptor agonist consistently outperforming semaglutide in trials. SURMOUNT-1: 20.9% weight loss. FDA approved as Mounjaro (T2D) and Zepbound (obesity). Current efficacy benchmark for GLP-1 class therapies.
BPC-157
therapeuticBPC-157 is a pentadecapeptide derived from a gastric juice protective protein. Over 100 animal studies demonstrate broad tissue-protective and healing effects. No completed human RCTs, but Phase II IBD trials have been conducted. One of the most-studied research peptides.
PT-141
therapeuticBremelanotide (PT-141) is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Acts centrally on brain melanocortin pathways governing sexual motivation — unlike PDE5 inhibitors which work peripherally. Also used off-label for male ED.
Sermorelin
therapeuticSermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) approved for pediatric growth hormone deficiency. It stimulates pituitary GH release through the body's own feedback mechanisms, making it a physiologically regulated alternative to exogenous HGH.
Thymosin Alpha-1
therapeuticThymosin Alpha-1 is one of the most clinically validated immune peptides. Approved as Zadaxin in 35+ countries for hepatitis B/C and cancer immunotherapy. Meta-analysis of 7 RCTs shows significant mortality reduction in sepsis. Gold standard immune peptide.
Browse by Condition
Relevant peptides organized by clinical indication
Latest Intel
Regulatory updates, research breakdowns, market intelligence
PCAC Backs 6 of 7 Peptides for 503A Compounding List: Full Vote Results
The FDA's Pharmacy Compounding Advisory Committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon for the 503A Bulk Drug Substances List. DSIP was the sole rejection.
4 min · 2026-07-27
RegulatoryFDA Advisory Committee Votes Yes on BPC-157 and KPV — Against Its Own Staff's Recommendation
In an unprecedented move, the FDA's Pharmacy Compounding Advisory Committee voted to recommend BPC-157 and KPV for the 503A bulks list — overruling FDA staff who said the evidence doesn't support it. Here's what happened and what it means.
7 min · 2026-07-23
ClinicalCJC-1295 with DAC vs. Without: Understanding the Half-Life Tradeoff
The DAC modification extends half-life from minutes to days. Cover the pharmacokinetic tradeoff, blunted pulsatile GH re...
3 min · 2026-07-09
Find a practitioner. Or become one.
Ercle's provider directory connects patients who've done their research with practitioners who prescribe evidence-based peptide protocols.
Find a Provider
Browse vetted practitioners who prescribe peptide protocols. Filter by specialty, location, and telehealth availability.
Browse directory →List Your Practice
Get in front of high-intent patients who've already researched their protocol. Listings from free — featured from $99/mo.
Get listed →Weekly Intelligence
The Peptide Evidence Briefing
Regulatory updates, new study breakdowns, and evidence reviews — delivered every week. Free.
No spam. Unsubscribe anytime. No vendor relationships.
Evidence-Rated
Every entry rated Strong, Moderate, Preliminary, or Insufficient. No grade inflation.
No Vendor Bias
No compensation from peptide vendors, compounding pharmacies, or supplement companies. Ever.
Regulatory Honest
We state what's approved, what's compoundable, and what's research-only. No euphemisms.